ABCESS2
A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients Versus Tetracycline Derivative
Sponsor study identifier
interventional
92
1 country
4
Study Start
May 22, 2025
Actual (reported)Primary Completion
February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 27, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 27, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 16, 2019
Actual (reported)April 20, 2023
Actual (reported)May 22, 2025
Actual (reported)February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 27, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Percentage of patients reaching clinical remission at week 12, defined by an improvement of 90% of the IHS4 score from the baseline (IHS4 (1))
The clinical remission is defined as a 90% improvement of the International Hidradenitis Suppurativa Severity Score (IHS4) at week 12 compared to the baseline. The IHS4 score is a validated composite score developped to assess dynamically HS severity (1). It is calculated by adding the number of inflammatory nodules to the number of abscesses multiplied by 2 and to the number of draining tunnels multiplied by 4. A total score of 3 or less corresponds to mild severity HS, 4-10 to moderate severity HS and 11 or higher to severe disease.
at week 12
Change in Physician Global Assessment (PGA)
from baseline to week 52
Change in Modified Sartorius score
from baseline to week 52
Change in Hurley Score
from baseline to week 52
Change in Hidradenitis Suppurativa Severity Score (IHS4) score
from baseline to week 52
Change in Hidradenitis Suppurativa Clinical Response (HiSCR) score
from baseline to week 52
a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day) \+ oral metronidazole (daily dose 1500mg) followed by a 3-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg) + metronidazole (daily dose 1500mg) followed by a 6-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg). A placebo for lymecycline will also be administered during this intensive treatment phase
12-week course of oral lymecycline (Tetralysal daily dose 452mg) Placebos for all experimental drugs will also be administered during this intensive treatment phase
a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Avalox® 400 mg Filmtabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordFormulated product
FLAGYL 250 mg, comprimé pelliculé
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordFormulated product
RIFADINE 300 mg, gélule
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
View registry recordFormulated product
MOXIFLOXACINE SANDOZ 400 mg, comprimé pelliculé
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordFormulated product
TETRALYSAL 150 mg, gélule
The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Avalox® 400 mg Filmtabletten
Named ingredient: Moxifloxacin
View registry recordFLAGYL 250 mg, comprimé pelliculé
Named ingredient: Metronidazole
View registry recordRIFADINE 300 mg, gélule
Named ingredient: Rifampicin
View registry recordMOXIFLOXACINE SANDOZ 400 mg, comprimé pelliculé
Named ingredient: Moxifloxacin
View registry recordTETRALYSAL 150 mg, gélule
Named ingredient: Lymecycline
View registry recordMOXIFLOXACINE SANDOZ 400 mg, comprimé pelliculé
Named ingredient: Moxifloxacin
View registry recordIZILOX 400 mg, comprimé pelliculé
Named ingredient: Moxifloxacin
Hôpital de la Timone
Marseille, France
Centre Médical de l'Institut Pasteur
Paris, France
Guet-Revillet H, Jais JP, Ungeheuer MN, Coignard-Biehler H, Duchatelet S, Delage M, Lam T, Hovnanian A, Lortholary O, Nassif X, Nassif A, Join-Lambert O. The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study. Clin Infect Dis. 2017 Jul 15;65(2):282-291. doi: 10.1093/cid/cix285.
Guet-Revillet H, Coignard-Biehler H, Jais JP, Quesne G, Frapy E, Poiree S, Le Guern AS, Le Fleche-Mateos A, Hovnanian A, Consigny PH, Lortholary O, Nassif X, Nassif A, Join-Lambert O. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014 Dec;20(12):1990-8. doi: 10.3201/eid2012.140064.
Maïa Delage-Toriel, MD
Institut Pasteur
First Submitted
April 16, 2019
First Posted
April 20, 2023
Study Start
May 22, 2025
Actual (reported)Primary Completion
12-week course of oral lymecycline.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
Formulated product
MOXIFLOXACINE SANDOZ 400 mg, comprimé pelliculé
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordFormulated product
IZILOX 400 mg, comprimé pelliculé
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordContact the study team to confirm eligibility.
Hopital St Joseph
Paris, France
CHU de Rouen
Rouen, France
Join-Lambert O, Coignard H, Jais JP, Guet-Revillet H, Poiree S, Fraitag S, Jullien V, Ribadeau-Dumas F, Theze J, Le Guern AS, Behillil S, Lefleche A, Berche P, Consigny PH, Lortholary O, Nassif X, Nassif A. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011 Feb;222(1):49-58. doi: 10.1159/000321716. Epub 2010 Nov 25.
February 28, 2027
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 27, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 9, 2025
Record last verified: 2025-07
All IPD that underlie results in a publication
Study fields come from the primary record; confirmed relationships can use other sources. Selecting a record here changes its provenance and downloads, without replacing the displayed study fields.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: